KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Asset Writedowns and Impairment: 2022-2025

  • Recursion Pharmaceuticals' Asset Writedowns and Impairment rose 5414.81% to $6.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $7.3 million, marking a year-over-year increase of 76.79%. This contributed to the annual value of $108,000 for FY2024, which is 90.91% down from last year.
  • As of Q1 2025, Recursion Pharmaceuticals' Asset Writedowns and Impairment stood at $6.0 million, which was up 5,414.81% from $108,000 recorded in Q1 2024.
  • In the past 5 years, Recursion Pharmaceuticals' Asset Writedowns and Impairment registered a high of $6.0 million during Q1 2025, and its lowest value of $19,000 during Q3 2023.
  • Over the past 3 years, Recursion Pharmaceuticals' median Asset Writedowns and Impairment value was $638,500 (recorded in 2023), while the average stood at $1.8 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Asset Writedowns and Impairment tumbled by 90.76% in 2024, and later soared by 5,414.81% in 2025.
  • Quarterly analysis of 4 years shows Recursion Pharmaceuticals' Asset Writedowns and Impairment stood at $2.8 million in 2022, then reached $19,000 in 2023, then crashed by 90.76% to $108,000 in 2024, then soared by 5,414.81% to $6.0 million in 2025.
  • Its Asset Writedowns and Impairment was $6.0 million in Q1 2025, compared to $108,000 in Q1 2024 and $19,000 in Q3 2023.